consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013
consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013
consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
286<br />
Primer Cons<strong>en</strong>so Nacional <strong>de</strong> cáncer <strong>epitelial</strong> <strong>de</strong> <strong>ovario</strong><br />
2010;376(9747):1155-1163.<br />
2. Markman M, Rothman R, Hakes T, Reichman B,<br />
Hoskins W, Rubin S, et al. Second-line platinum<br />
therapy in pati<strong>en</strong>ts with ovarian cancer previously<br />
treated with cisplatin. J Clin Oncol. 1991;9:389-393.<br />
3. Zanaboni F, Scarfone G, Presti M, Maggi R, Borello<br />
C, Bolis G. Salvage chemotherapy for ovarian<br />
cancer recurr<strong>en</strong>ce: Weekly cisplatin in combination<br />
with epirubicin or etoposi<strong>de</strong>. Gynecol Oncol.<br />
1991;43(1):24-28.<br />
4. Ferrandina G, Ludovisi M, De Vinc<strong>en</strong>zo R, Salutari<br />
V, Lorusso D, Colangelo M, et al. Docetaxel and<br />
oxaliplatin in the second-line treatm<strong>en</strong>t of platinums<strong>en</strong>sitive<br />
recurr<strong>en</strong>t ovarian cancer: A phase II study.<br />
Ann Oncol. 2007;18(8):1348-1353.<br />
5. van <strong>de</strong>r Burg ME, Hoff AM, van L<strong>en</strong>t M, Rod<strong>en</strong>burg<br />
CJ, van Putt<strong>en</strong> WL, Stoter G. Carboplatin and<br />
cyclophosphami<strong>de</strong> salvage therapy for ovarian<br />
cancer pati<strong>en</strong>ts relapsing after cisplatin combination<br />
chemotherapy. Eur J Cancer. 1991;27(3):248-250.<br />
6. Weiss G, Gre<strong>en</strong> S, Alberts DS, Thigp<strong>en</strong> JT, Hines<br />
HE, Hanson K, et al. Second-line treatm<strong>en</strong>t of<br />
advanced measurable ovarian cancer with iproplatin:<br />
A Southwest Oncology Group Study. Eur J Cancer.<br />
1991;27(2):135-138.<br />
7. Rose PG, Fusco N, Fluell<strong>en</strong> L, Rodriguez M.<br />
Second-line therapy with paclitaxel and carboplatin<br />
for recurr<strong>en</strong>t disease following first-line therapy<br />
with paclitaxel and platinum in ovarian or peritoneal<br />
carcinoma. J Clin Oncol. 1998;16(4):1494-1497.<br />
8. Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez<br />
GC. The combination of monthly carboplatin and<br />
weekly paclitaxel is highly active for the treatm<strong>en</strong>t<br />
of recurr<strong>en</strong>t ovarian cancer. Gynecol Oncol.<br />
2009;115(3):377-381.<br />
9. Bolis G, Scarfone G, Giardina G, Villa A, Mangili<br />
G, Melpignano M, et al. Carboplatin alone vs.<br />
carboplatin plus epidoxorubicin as second-line therapy<br />
for cisplatin- or carboplatin-s<strong>en</strong>sitive ovarian cancer.<br />
Gynecol Oncol. 2001;81(1):3-9.<br />
10. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte<br />
H, Lacave AJ, et al. Gemcitabine plus carboplatin<br />
compared with carboplatin in pati<strong>en</strong>ts with platinums<strong>en</strong>sitive<br />
recurr<strong>en</strong>t ovarian cancer: An intergroup trial<br />
of the AGO-OVAR, the NCIC CTG, and the EORTC<br />
GCG. J Clin Oncol. 2006;24(29):4699-4707.<br />
11. Markman M, Moon J, Wilczynski S, Lopez AM,<br />
Rowland KM Jr, Michelin DP, et al. Single ag<strong>en</strong>t<br />
carboplatin versus carboplatin plus pegylated<br />
liposomal doxorubicin in recurr<strong>en</strong>t ovarian cancer:<br />
Final survival results of a SWOG (S0200) phase 3<br />
randomized trial. Gynecol Oncol. 2010;116(3):323-<br />
325.<br />
12. Puja<strong>de</strong>-Lauraine E, Wagner U, Aavall-Lundqvist E,<br />
Gebski V, Heywood M, Vasey PA, et al. Pegylated<br />
liposomal doxorubicin and carboplatin compared with<br />
paclitaxel and carboplatin for pati<strong>en</strong>ts with platinums<strong>en</strong>sitive<br />
ovarian cancer in late relapse. J Clin Oncol.<br />
2010;28(20):3323-3329<br />
13. Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman<br />
K, Sugimoto A, et al. Decreased hypers<strong>en</strong>sitivity<br />
reactions with carboplatin-pegylated liposomal<br />
doxorubicin compared to carboplatin-paclitaxel<br />
combination: Analysis from the GCIG CALYPSO<br />
relapsing ovarian cancer trial. Gynecol Oncol.<br />
2011;122(2):226-232.<br />
14. Joly F, Petit T, Pautier P, Guardiola E, Mayer F,<br />
Chevalier-Place A, et al. Weekly combination of<br />
topotecan and gemcitabine in early recurr<strong>en</strong>t ovarian<br />
cancer pati<strong>en</strong>ts: A Fr<strong>en</strong>ch multic<strong>en</strong>ter phase II study.<br />
Gynecol Oncol. 2009;115(3):382-388.<br />
15. Monk BJ, Herzog TJ, Kaye SB, Krasner CN,<br />
Vermork<strong>en</strong> JB, Muggia FM, et al. Trabectedin plus<br />
pegylated liposomal doxorubicin in recurr<strong>en</strong>t ovarian<br />
cancer. J Clin Oncol. 2010;28(19):3107-3114.<br />
16. X<strong>en</strong>idis N, Neanidis K, Amarantidis K, Dimopoulos P,<br />
Chamalidou E, Pitsiava D, et al. Biweekly vinorelbine<br />
and gemcitabine as second-line and beyond treatm<strong>en</strong>t<br />
in ovarian cancer. Cancer Chemother Pharmacol.<br />
2011;67(1):69-73.<br />
17. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M,<br />
Chan S, et al. Trabectedin plus pegylated liposomal<br />
doxorubicin in relapsed ovarian cancer: Outcomes in<br />
the partially platinum-s<strong>en</strong>sitive (platinum-free interval<br />
6-12 months) subpopulation of OVA-301 phase III<br />
randomized trial. Ann Oncol. 2011;22(1):39-48.<br />
18. Aghajanian C, Blank SV, Goff BA, Judson PL,<br />
T<strong>en</strong>eriello MG, Husain A, et al. OCEANS: A<br />
randomized, double-blind, placebo-controlled phase<br />
III trial of chemotherapy with or without bevacizumab<br />
in pati<strong>en</strong>ts with platinum-s<strong>en</strong>sitive recurr<strong>en</strong>t epithelial<br />
ovarian, primary peritoneal, or fallopian tube cancer.<br />
J Clin Oncol. 2012;30(17):2039-2045.<br />
19. Rose PG, Blessing JA, Mayer AR, Homesley HD.<br />
Prolonged oral etoposi<strong>de</strong> as second-line therapy for<br />
platinum-resistant and platinum-s<strong>en</strong>sitive ovarian<br />
carcinoma: A Gynecologic Oncology Group study. J<br />
Clin Oncol. 1998;16(2):405-410.<br />
20. Gordon AN, Fleagle JT, Guthrie D, Parkin DE,<br />
Gore ME, Lacave AJ. Recurr<strong>en</strong>t epithelial ovarian<br />
Vol. 26, Nº 3, septiembre 2014